You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 664 A phase I trial of tremelimumab, durvalumab (MEDI4736) and belinostat in ARID1A mutated cancers with focus on urothelial carcinoma (RESOLVE)

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
664 A phase I trial of tremelimumab, durvalumab (MEDI4736) and belinostat in ARID1A mutated cancers with focus on urothelial carcinoma (RESOLVE)
Free

Authors

Citation

Gupta S, Maughan B, Kohli M, et al
664 A phase I trial of tremelimumab, durvalumab (MEDI4736) and belinostat in ARID1A mutated cancers with focus on urothelial carcinoma (RESOLVE)
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0664

Publication history

  • First published November 7, 2022.
Online issue publication 
April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.